doi: 10.1016/S0140-6736(08)60694-7 47 GrysiewiczRAThomasKPandeyDK
In April, Rascols team published research in the New England Journal of Medicine that found the GLP-1 drug lixisenatide reduced movement-related symptoms in people with early stage Parkinsons (2024, DOI: 10.1056/NEJMoa2312323)
10.1208/s12248-008-9022-y AAPS J
Yusta B, Baggio LL, Koehler J, Holland D, Cao X, Pinnell LJ, Johnson-Henry KC, Yeung W, Surette MG, Bang KW
Department of Labor, New York Office of the Solicitor
This guide will help you understand why insurance coverage for GLP-1 drugs for weight loss is so limited, what new options are emerging, and exactly what steps you can take to advocate for access